| Pharmaceutical Information |
| Drug Name |
Cyproheptadine |
| Drug ID |
BADD_D00552 |
| Description |
Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors.[L32474] It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of serotonin syndrome.[A231274] |
| Indications and Usage |
In the US, prescription cyproheptadine is indicated for the treatment of various allergic symptomatologies - including dermatographia, rhinitis, conjunctivitis, and urticaria - as well as adjunctive therapy in the management of anaphylaxis following treatment with epinephrine.[L32474] In Canada, cyproheptadine is available over-the-counter and is indicated for the treatment of pruritus and for appetite stimulation.[L32519] In Australia, cyproheptadine is additionally indicated for the treatment vascular headaches.[L32479]
Cyproheptadine is also used off-label for the treatment of serotonin syndrome.[A231274] |
| Marketing Status |
approved |
| ATC Code |
R06AX02 |
| DrugBank ID |
DB00434
|
| KEGG ID |
D07765
|
| MeSH ID |
D003533
|
| PubChem ID |
2913
|
| TTD Drug ID |
D00TLN
|
| NDC Product Code |
Not Available |
| UNII |
2YHB6175DO
|
| Synonyms |
Cyproheptadine | Dihexazin | Peritol | Viternum | Antergan | Periactin |
|
| Chemical Information |
| Molecular Formula |
C21H21N |
| CAS Registry Number |
129-03-3 |
| SMILES |
CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
